Sotera Health (NASDAQ:SHC) Shares Bought by Maverick Capital Ltd.

Maverick Capital Ltd. grew its position in shares of Sotera Health (NASDAQ:SHC) by 3.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,497,367 shares of the company’s stock after acquiring an additional 118,353 shares during the quarter. Maverick Capital Ltd.’s holdings in Sotera Health were worth $58,406,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SHC. CWM LLC boosted its holdings in Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the last quarter. GAMMA Investing LLC increased its position in Sotera Health by 125.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock valued at $50,000 after acquiring an additional 1,660 shares during the period. Point72 DIFC Ltd increased its position in shares of Sotera Health by 556.6% during the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after purchasing an additional 5,544 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Sotera Health during the 3rd quarter valued at $91,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 728.0% during the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after acquiring an additional 8,248 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SHC has been the subject of several research reports. Barclays raised their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Citigroup raised their price target on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Activity

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. The trade was a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 55.12% of the company’s stock.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $13.17 on Friday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The firm has a market cap of $3.73 billion, a price-to-earnings ratio of 52.68 and a beta of 2.08. The business’s 50-day simple moving average is $15.25 and its 200-day simple moving average is $14.01. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.18 EPS. As a group, equities research analysts expect that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.